FORM 3

HCA Healthcare, Inc. - HCA

Filed: November 03, 2017 (period: November 01, 2017)

Initial statement of beneficial ownership of securities
**1. Name and Address of Reporting Person**

Reiner Deborah M  

(Street) ONE PARK PLAZA  

(City) NASHVILLE TN  

(State) TN  

(Zip) 37203

**2. Date of Event Requiring Statement (Month/Day/Year)**  

11/01/2017

**3. Issuer Name and Ticker or Trading Symbol**  

HCA Healthcare, Inc. [HCA]

**4. Relationship of Reporting Person(s) to Issuer (Check all applicable)**

- Director  
- 10% Owner  
- Officer (give title below)  
- SVP - Mktg. & Communications

**5. If Amendment, Date of Original Filed (Month/Day/Year)**

**6. Individual or Joint/Group Filing (Check Applicable Line)**

- Form filed by One Reporting Person  
- Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 4)</th>
<th>2. Amount of Securities Beneficially Owned (Instr. 4)</th>
<th>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>4. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>2,020</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Beneficially Owned

- (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 4)</th>
<th>2. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</th>
<th>4. Conversion or Exercise Price of Derivative Security</th>
<th>5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>6. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Appreciation Right</td>
<td>(1) 02/08/2022 Common Stock 2,500 22.95 D</td>
<td>Stock Appreciation Right</td>
<td>Stock Appreciation Right 2,500 22.95 D</td>
<td>Stock Appreciation Right 2,500 22.95 D</td>
<td>Stock Appreciation Right 2,500 22.95 D</td>
</tr>
<tr>
<td>Stock Appreciation Right</td>
<td>(2) 02/08/2022 Common Stock 2,500 22.95 D</td>
<td>Stock Appreciation Right</td>
<td>Stock Appreciation Right 2,500 22.95 D</td>
<td>Stock Appreciation Right 2,500 22.95 D</td>
<td>Stock Appreciation Right 2,500 22.95 D</td>
</tr>
<tr>
<td>Stock Appreciation Right</td>
<td>(3) 02/05/2024 Common Stock 4,500 47.97 D</td>
<td>Stock Appreciation Right</td>
<td>Stock Appreciation Right 4,500 47.97 D</td>
<td>Stock Appreciation Right 4,500 47.97 D</td>
<td>Stock Appreciation Right 4,500 47.97 D</td>
</tr>
<tr>
<td>Stock Appreciation Right</td>
<td>(4) 02/05/2024 Common Stock 3,150 47.97 D</td>
<td>Stock Appreciation Right</td>
<td>Stock Appreciation Right 3,150 47.97 D</td>
<td>Stock Appreciation Right 3,150 47.97 D</td>
<td>Stock Appreciation Right 3,150 47.97 D</td>
</tr>
<tr>
<td>Stock Appreciation Right</td>
<td>(5) 02/04/2024 Common Stock 6,000 69.58 D</td>
<td>Stock Appreciation Right</td>
<td>Stock Appreciation Right 6,000 69.58 D</td>
<td>Stock Appreciation Right 6,000 69.58 D</td>
<td>Stock Appreciation Right 6,000 69.58 D</td>
</tr>
<tr>
<td>Stock Appreciation Right</td>
<td>(6) 01/29/2026 Common Stock 5,980 69.58 D</td>
<td>Stock Appreciation Right</td>
<td>Stock Appreciation Right 5,980 69.58 D</td>
<td>Stock Appreciation Right 5,980 69.58 D</td>
<td>Stock Appreciation Right 5,980 69.58 D</td>
</tr>
<tr>
<td>Stock Appreciation Right</td>
<td>(7) 02/01/2027 Common Stock 6,420 81.96 D</td>
<td>Stock Appreciation Right</td>
<td>Stock Appreciation Right 6,420 81.96 D</td>
<td>Stock Appreciation Right 6,420 81.96 D</td>
<td>Stock Appreciation Right 6,420 81.96 D</td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>02/05/2024 Common Stock 375 (k) D</td>
<td>Restricted Stock Units</td>
<td>Restricted Stock Units 375 (k) D</td>
<td>Restricted Stock Units 375 (k) D</td>
<td>Restricted Stock Units 375 (k) D</td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. The stock appreciation rights vested in four equal annual installments beginning on February 8, 2013.
2. The stock appreciation rights vested at the end of fiscal years 2012, 2013, 2014 and 2015 based upon the achievement of certain annual EBITDA performance targets.
3. The stock appreciation rights vest in four equal annual installments beginning on February 5, 2015.
4. On February 5, 2014, the reporting person was granted 4,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company’s achievement of EBITDA performance criteria for 2014, 2015 and 2016, 3,150 of such stock appreciation rights have vested.
5. The stock appreciation rights vest in four equal annual installments beginning on February 4, 2016.
7. The stock appreciation rights vest in four equal annual installments beginning on February 1, 2018.
8. Each restricted stock unit represents a contingent right to receive one share of HCA Healthcare, Inc. common stock.

**Remarks:**

/\ Kevin A. Ball, Attorney-in-Fact  

11/03/2017

**Reminder:** Report on a separate line for each class of securities beneficially owned directly or indirectly.

*If the form is filed by more than one reporting person, see Instruction 5 (b)(v).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: HCA Healthcare, Inc., 3, November 03, 2017
Powered by Morningstar® Document Research℠
The information contained herein may not be copied, adapted or distributed and is not warranted to be accurate, complete or timely. The user assumes all risks for any damages or losses arising from any use of this information, except to the extent such damages or losses cannot be limited or excluded by applicable law. Past financial performance is no guarantee of future results.
POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints John M. Franck II, Natalie Harrison Cline and Kevin A. Ball as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

(1) prepare, execute, acknowledge, deliver and file a Form ID (including any amendments or authentications thereto) with respect to obtaining EDGAR codes, with the U.S. Securities and Exchange Commission;

(2) prepare, execute, acknowledge, deliver and file Forms 3, 4 and 5 (including any amendments thereto) with respect to the securities of HCA Healthcare, Inc., a Delaware corporation (the "Company"), with the U.S. Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");

(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

(4) perform any and all other acts which in the discretion of such attorneys-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

(1) this Power of Attorney authorizes, but does not require, such attorneys-in-fact to act in their discretion on information provided to such attorneys-in-fact without independent verification of such information;

(2) any documents prepared and/or executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

(3) neither the Company nor such attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

(4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, with full power of substitution and revocation, hereby ratifying all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of October 2017.

/s/ Deborah M. Reiner
Print Name: Deborah M. Reiner